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A B S T R A C T
Introduction: Type 2 diabetes (T2D) is a common comorbidity in patients with schizophrenia (SCZ). The un-
derlying pathophysiologic mechanisms are yet to be fully elucidated, although it can be argued that shared
genes, environmental factors or their interaction effect are involved. This study investigated the association
between polygenic risk score of SCZ (PRSSCZ) and glycated haemoglobin (HbA1c) while adjusting for polygenic
risk score of T2D (PRST2D), and clinical and demographic covariables.
Methods: Genotype, clinical and demographic data of 1129 patients with non-affective psychosis were extracted
from Genetic Risk and Outcome of Psychosis (GROUP) cohort study. The glycated haemoglobin (HbA1c) was the
outcome. PRS was calculated using standard methods. Univariable and multivariable linear regression analyses
were applied to estimate associations. Additionally, sensitivity analysis based on multiple imputation was done.
After correction for multiple testing, a two-sided p-value ≤.003 was considered to discover evidence for an
association.
Results: Of 1129 patients, 75.8% were male with median age of 29 years. The mean (standard deviation) HbA1c
level was 35.1 (5.9) mmol/mol. There was no evidence for an association between high HbA1c level and in-
creased PRSSCZ (adjusted regression coefficient (aβ)= 0.69, standard error (SE)= 0.77, p-value= .37). On the
other hand, there was evidence for an association between high HbA1c level and increased PRST2D (aβ= 0.93,
SE= 0.32, p-value= .004), body mass index (aβ=0.20, SE= 0.08, p-value= .01), diastolic blood pressure
(aβ= 0.08, SE=0.04, p-value= .03), late age of first psychosis onset (aβ=0.19, SE= 0.05, p-value= .0004)
and male gender (aβ=1.58, SE=0.81, p-value= .05). After multiple testing correction, there was evidence for
an association between high HbA1c level and late age of first psychosis onset. Evidence for interaction effect
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between PRSscz and antipsychotics was not observed. The multiple imputation-based sensitivity analysis pro-
vided consistent results with complete case analysis.
Conclusions: Glycemic dysregulation in patients with SCZ was not associated with PRSSCZ. This suggests that the
mechanisms of hyperglycemia or diabetes are at least partly independent from genetic predisposition to SCZ. Our
findings show that the change in HbA1c level can be caused by at least in part due to PRST2D, late age of illness
onset, male gender, and increased body mass index and diastolic blood pressure.
1. Introduction
Schizophrenia (SCZ) is a heterogeneous psychiatric disorder mani-
fested by positive (i.e., delusions and hallucinations) and negative (i.e.,
impaired motivation, social withdrawal and reduction in spontaneous
speech) symptoms [1]. SCZ shortens life expectancy by 15–30 years
compared to the general population [2,3], of which approximately 60%
is caused by co-occurring somatic diseases, such as type 2 diabetes
(T2D) [4]. Metabolic disorders, including T2D, have been common
long-term complications in patients with SCZ [5]. The worldwide pre-
valence of T2D among patients with SCZ is 10.8% [6] and the pre-
valence in Dutch patients with SCZ is 15.3% [7]. Besides, increased
level of glycated haemoglobin (HbA1c) is observed in 14.4% [8], im-
paired fasting blood glucose in 15.0% [9] and impaired glucose toler-
ance in 14.0% [10] of patients with SCZ. Further evidence shows an
increase in blood glucose and hepatic insulin resistance in patients with
first-episode psychosis or antipsychotic naïve patients [11,12].
Epidemiologic evidence suggests a shared (pleiotropic) genetic ae-
tiology between T2D and SCZ that explains part of the aforementioned
comorbidity [13]. First, individuals born from a mother with gesta-
tional diabetes have a seven-fold increased risk of SCZ later in life [14].
Second, family history of SCZ is significantly associated with a family
history of T2D and vice versa [15–18]. Third, the co-occurrence of T2D
and SCZ has been reported before the discovery of antipsychotics,
leaving T2D more likely to be associated with genetic aetiology of SCZ
[19]. Furthermore, a recent genome-wide association study (GWAS)
and polygenic risk score analysis identified 29 shared genes and sig-
nificant association between polygenic risk scores of the two diseases
[20]. An advanced network and pathway-based analysis also depicted
shared pathogenetic association between SCZ and T2D [21–23].
Beyond the possibility of shared genetic susceptibility, several
longitudinal, randomized controlled trial and meta-analysis studies
[24–28] show that the use of antipsychotic drugs has also been in-
dependently associated with metabolic disturbances in SCZ. For ex-
ample, use of olanzapine substantially increases blood glucose level and
the risk of T2D up to 59% among patients with SCZ [29–31] even
though individual differences of susceptibility to antipsychotics-in-
duced cardiometabolic impairment is observed [32–36]. Similar to the
general population, glycaemic dysregulation among people with SCZ
can also be associated with demographic and clinical diabetogenic risk
factors [5,13,37,38].
In spite of these broad ranges of evidence, variation in diagnostic
criteria or use of phenotype for T2D, study population, sample size and
number of single nucleotide polymorphisms (SNPs) used to construct
polygenic risk score (PRS) has been observed between studies.
Moreover, comorbidity studies to explore the genetic bases of these two
diseases are scarce due to the complex nature of the diseases and un-
derdiagnosis of T2D patients. So, the findings have been inconsistent,
and it is not yet fully elucidated who of SCZ patients may develop
glucose dysregulation and T2D. In this study, we aimed to investigate
the association between polygenic risk score of SCZ (PRSSCZ) and gly-
cated haemoglobin level (HbA1c) while adjusting for polygenic risk
score of T2D (PRST2D), and clinical and demographic covariables. We
hypothesized that PRSSCZ significantly associated with high glycated
haemoglobin level HbA1c.
2. Methods
2.1. Study population
Data release 7.00 of Genetic Risk and Outcome of Psychosis
(GROUP) cohort study was used for this study. GROUP is a multi-centre
longitudinal cohort study in the Netherlands, which constituted of pa-
tients, parents, siblings and controls [39]. Details of the original cohort
were explained elsewhere [39]. Patients with non-affective psychotic
disorders, age between 16 and 50 years and good command of the
Dutch language were included. In GROUP cohort study, data were
collected at baseline, and after three years and six years. In the present
study, 1129 eligible patients who had cardiometabolic data that have
been collected only on the second wave of assessment at the third year
of follow-up were included. Genotype, clinical and demographic data
were collected from patients after obtaining verbal and written in-
formed consent.
2.2. Genotyping and quality control (QC)
Genotyping of samples performed using Illumina and Affymetrix
platforms. The DNA data of 1434 individuals (758 patients and 676
controls) were genotyped for 547,383 single nucleotide polymorphisms
(SNPs) using Illumina HumanHap 550 k version 3.0 beadchip (https://
www.illumina.com). Besides, the DNA data of 1968 individuals (393
patients, 154 controls and 1421 healthy relatives) were genotyped for
929,556 SNPs using Affymetrix genome-wide Human SNP Array ver-
sion 6.0 (http://www.affymetrix.com/estore/index.jsp). Thirty-six
participants were excluded because of sex mismatch (i.e. discrepancy
between the recorded and genetically determined sex) and five parti-
cipants due to genotype missing rate> 10%. SNPs were excluded if
haploid, a missing rate per SNP was >0.10, a minor allele fre-
quency<0.01 and a Hardy–Weinberg equilibrium (HWE) p-value
<1×10−6. Moreover, pruning was done using a window/step size of
50 kb/5 and r2> 0.2 [40]. As a result, 515,286 SNPs and 1393 in-
dividuals (737 cases and 656 controls) passed QC for further analysis.
Similarly, 729,597 SNPs and 1968 individuals genotyped using Affy-
metrix passed QC. The genomic coordinate of all sample SNPs (except
for 57 from Illumina and 86 from Affymetrix) was converted from
Human NCBI36/hg18 to Human GRCh37/hg19 using liftover [41]. As
implemented in the Haplotype Reference Consortium (HRC) [42], both
platform samples were imputed on the backbone of 1000G Phase-3
reference haploblocks by using Michigan Imputation Server and option
of SHAPEIT for phasing. This yielded 46,178,415 imputed SNPs, which
was down to 16,353,433 SNPs after selecting SNPs with a quality score
(info score) threshold of >0.30. Of these, 9,067,392 SNPs and 1393
subjects passed the post-imputation QC. For Affymetrix genotyped
SNPs, 1000G based imputation yielded 46,178,419 imputed SNPs, and
9,122,501 SNPs and 1968 individuals passed the post-imputation QC.
Genotype QC was carried out using PLINK toolset version 1.9 [43].
2.3. Polygenic risk score calculation
The summary statistics of the 62 T2D risk SNPs (p<5×10−8)
were obtained from the DIAbetes Genetics Replication And Meta-ana-
lysis (DIAGRAM) consortium, a meta-analysis of GWAS with more than
34,840 cases and 114,981 controls (Table S1) [44,45]. The summary
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statistics of the SCZ risk SNPs were obtained from the phase 2 Psy-
chiatric Genomics Consortium (PGC-2), a meta-GWAS of SCZ with
36,989 cases and 113,075 controls (Table S2) [46]. There was no
sample overlap between the study sample and SCZ/T2D GWAS. Poly-
genic risk scores were calculated for each individual using PRSice
software version 1.25 for Windows [47] as a sum of the number of risk
alleles multiplied by their corresponding effect sizes (i.e. the logs of the
OR) across genetic loci. It is well known that PRSSCZ is more predictive
when including a larger number of genetic markers [48], so that PRS
was calculated using five p-value thresholds (i.e. 5× 10−8, 5×10−4,
0.01, 0.05, 0.1). We used PRS, which is built of SNPs associated with
SCZ at a p-value threshold (PT) of ≤0.05 given that this has been re-
ported to be the most predictive threshold for SCZ [46]. However, for
T2D, PRS was calculated based on p-value threshold <5×10−8 given
that evidence on the predictive power of genome-wide non-significant
SNPs is lacking. To control for the population stratification effect, the
PRS was adjusted for the first ten ancestry principal components esti-
mated by EIGENSTRAT software version 3.2.4 [49]. Finally, we stan-
dardized the PRS to a standard normal distribution (mean of 0 and
standard deviation of 1) for ease of interpretations [50].
2.4. Measurement variables
Glycated haemoglobin level (HbA1c) in mmol/mol, which is one of
the phenotypes of T2D, was the outcome variable. The main exposure
variable was PRSSCZ. The covariables were PRST2D, clinical indicators
(i.e., age of psychosis onset, duration of illness, episode of psychosis,
presence of comorbid diseases, physical examination reports and la-
boratory test reports) and demographic characteristics (i.e., gender,
age, ethnicity, marital status, cigarette smoking and alcohol drinking).
Physical examination report includes body mass index (kg/m2), umbi-
lical waist circumference (cm), blood pressure (mmHg) and pulse rate
(beats/min), whereas laboratory test report includes triglycerides
(mmol/l), high-density lipoprotein (mmol/l), low-density lipoprotein
(mmol/l). Reported comorbid diseases were hematologic, hormonal,
metabolic, heart, vascular, liver-bilious-pancreas-spleen, abdominal/
gastrointestinal and kidney disorders. Moreover, platform/batch effect
indicating the variance in PRS due to use of different genotyping
platforms (Illumina vs Affymetrix) was considered. Data were collected
from patient themselves or their therapists. The Comprehensive
Assessment of Symptoms and History (CASH) [51] and Schedules for
Clinical Assessment for Neuropsychiatry (SCAN) [52] structured ques-
tionnaire were used to assess psychotic disorders. Diagnosis was made
based on the fourth text-edition of Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) axis one [53]. We classified antipsychotics
as high metabolic risk (olanzapine and clozapine), moderate metabolic
risk (risperidone, quetiapine, amisulpride, pipamperone, levomepro-
mazine and sertindole), low metabolic risk (haloperidol, aripiprazole,
bromperidol, flupentixol, pimozide, sulpiride and zuclopenthixol), and
unknown metabolic risk (clotiapine and perphenazine) [25–27]. Anti-
psychotic drug dosage was calculated based on chlorpromazine
equivalents (CPZE), which is defined as the dose of a drug that is
equivalent to 100mg of oral dose of chlorpromazine. Patients without
prescription of antipsychotic drugs were classified as nonusers.
2.5. Statistical analyses
First, the predictors, which were identified through reading of
previous literature [5] and available in GROUP cohort study were in-
cluded in the univariable linear regression model. Those predictors with
a p-value of ≤0.25 in univariable analyses were included in the mul-
tivariable linear regression model. Next, considering our hypothesis and
the relatedness of variables to the outcome, we developed four hier-
archical models to adjust confounders and identify relevant in-
dependent predictors of high HbA1c. Model 1 included only PRSSCZ.
Model 2 included Model 1 and PRST2D, type of genotyping platform and
use of antipsychotics. Model 3 expanded Model 2 with cardiometabolic
profiles that included body mass index, waist circumference, blood
pressure, pulse, triglycerides, high-density lipoprotein and low-density
lipoprotein. Finally, Model 4 was an extension of Model 3 by inclusion
of age of onset of psychosis, duration of illness, gender, ethnicity,
current age, alcohol drinking and interaction term between PRSSCZ by
high-risk antipsychotics for metabolic disturbance. The best-fitting
model was selected using the Akaike Information Criterion (AIC),
Bayesian Information Criterion (BIC), Log-Likelihood (LL), and R2.
Multicollinearity in the best fitting model was investigated using the
variance inflation factor (VIF) (1.0 to 10.0) and tolerance (> 0.20)
statistics [54]. Since 18 variables were tested in model 4, to accom-
modate multiple hypothesis testing, the statistical significance two-
sided p-value was set to be 0.05 divided by 18 reaching at 0.003. We
reported evidence for an association using unstandardized coefficients
(i.e., regression coefficient (β) and standard error (SE)) along with the
p-value. The Statistical Package for the Social Sciences (SPSS) software
version 23.0, R software version 3.3.2 and PLINK toolset version 1.90
were used for data analyses.
2.6. Sensitivity analysis
To explore the amount and likely mechanisms of missingness in our
data, we analysed the patterns of data missingness. In addition, in-
dependent t-test for continuous variables and Chi-square test for cate-
gorical variables were performed to compare differences between
complete and missing cases, and test missing completely at random
(MCAR) or missing at random (MAR). Finally, missing data were han-
dled by multiple imputation (i.e., data were imputed 20 times) using
Markov chain Monte Carlo (MCMC) method assuming missing at
random (MAR). Predictive mean matching (PMM) model was used for
continuous variables and logistic regression model was used for cate-
gorical variables. A sensitivity analysis based on Model 4 was done
using the imputed dataset. We also performed sensitivity analysis after
excluding individuals with self-reported diabetes (N=10), and hor-
monal and metabolic disorders other than diabetes (N=7).
3. Results
3.1. Patient characteristics
Of 1129 patients, 75.8% were male and 79.2% were Caucasian. The
median (interquartile range (IQR)) age and age of onset of first psy-
chosis was 29 (10) years and 21 (9) years, respectively. The mean
(standard deviation) HbA1c was 35.1(5.9) mmol/mol. More than three-
quarters of patients (78.8%) have used antipsychotics. The median
(IQR) antipsychotic dosage was 300 (330) mg/day. In addition, 13.4%
of patients reported cardiometabolic diseases other than diabetes.
Detailed patient characteristics have shown below in Table 1.
3.2. Risk factors of high HbA1c
In the univariable regression model, there was evidence for an as-
sociation between high HbA1c level and PRSSCZ, PRST2D, use of anti-
psychotics and most cardiometabolic profiles (Table 2).
In the multivariable regression analysis, we built four models and
selected model 4 as the best-fitting model (BIC= 2304.82,
AIC= 2227.77, LL=−1093.88, R2= 19.20%) (Table 3). Waist cir-
cumference was excluded from model 4 due to collinearity with body
mass index, and current age was excluded due to collinearity with age
of first psychosis onset and duration of psychosis illness. There was no
evidence for an association between high HbA1c level and increased
PRSSCZ (adjusted regression coefficient (aβ)= 0.69, standard error
(SE)= 0.77, p-value= .37). The patient glycated haemoglobin level,
on average, was increased by 0.69mmol/mol for every increase of one
point (i.e., one standard deviation change) on the PRSSCZ. On the other
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hand, there was evidence for nominal association between high HbA1c
level and increased PRST2D (aβ=0.93, SE=0.32, p-value= .004),
body mass index (aβ= 0.20, SE= 0.08, p-value= .01), diastolic blood
pressure (aβ=0.08, SE=0.04, p-value= .03) and male gender
(aβ= 1.58, SE= 0.81, p-value= .05). After multiple testing correc-
tion, there was evidence for an association between high HbA1c level
and late age of first psychosis onset (aβ=0.19, SE=0.05, p-
value= .0004). Despite the adjustment for several covariables (models
2 to 4), the association between high HbA1c level and PRSSCZ was at-
tenuated solely due to platform effect. In a follow-up stratified analysis
by the genotyping platform, based on model 4, there was no evidence of
an association between high HbA1c level and PRSSCZ in both platforms.
In addition, the association between high HbA1c level and high meta-
bolic risk antipsychotics was attenuated only due to the interaction
term (model 4).
3.3. Missing data and sensitivity analysis
Data missingness pattern analysis showed that 16 out of 19 vari-
ables had at least one missing value and 781 patients had at least one
missing value on a variable (Fig. S1, Table S4). Overall, 28.13% of the
total sample data were missing (Fig. S1). As illustrated in Fig. S2, the
pattern of missing values seems random. Little's test was significant
(X2= 596.33, df= 339, p< .001), which indicate a lack of evidence
that support missingness completely at random (MCAR). The in-
dependent t-test (Table S5) and Chi-square test (Table S6) results
showed significant difference between complete and missing cases on
many variables, and missing values can be predicted based on other
variables, which support evidence of missing at random (MAR) and
assumption of multiple imputation. Finally, sensitivity analysis based
on multiple imputation provided consistent results with complete case
analysis.
4. Discussion
Whether shared genetic susceptibility to SCZ and T2D is predis-
posing to a high glycaemic level among patients with non-affective
psychosis has been an ongoing debate and yet to be investigated.
Though, the general body of current evidence suggests that anti-
psychotics play an important role in hyperglycaemia. One may suggest
that antipsychotics may not be significantly associated with high gly-
cemia level in the absence or low level of genetic susceptibility to SCZ
and/or T2D. To clarify this ambiguity, we investigated the association
between polygenic risk score of SCZ (PRSSCZ) and glycated hae-
moglobin level (HbA1c) while adjusting for polygenic risk score of T2D
(PRST2D), and clinical and demographic covariables in a relatively large
sample of patients with non-affective psychotic disorder that follows
the same diagnostic criteria and treatment guideline. In this study,
there was no evidence for an association between high HbA1c level and
increased PRSSCZ, whereas late age onset of psychosis found to be a
strong predictor associated with high HbA1c.
Our finding was in line with previous studies [55–59] that showed
weak or absence of association between PRSSCZ and high glycaemia
level or T2D. On the other hand, one study reported a positive asso-
ciation between high glycemia level and PRSSCZ while adjusting for the
use of antipsychotic medications [60] and another study [61] found a
negative association between PRSSCZ and high HbA1c level in patients
with SCZ. This discrepancy might be due to constructing PRS using
different version of the GWAS summary statistics [56–58,60], use of
different measurement of glycaemic state (e.g. self-reported diabetes or
laboratory reports) or different phenotype of T2D with different sensi-
tivity (e.g. fasting or random blood sugar) [60], lack of adjustment to
various important variables and inclusion of patients from different
ethnicities [55,58]. The use of more than one different genotyping tool
may also be a reason whereby Illumina and Affymetrix were used in our
study. Our analysis showed that, despite the adjustment for multiple
covariables, the association between high HbA1c level and PRSSCZ was
attenuated only due to platform effect. This can be due to the significant
difference in mean PRSSCZ between platforms (i.e., -1.01 for Illumina
and 0.75 for Affymetrix) though the stratified analysis did not show
evidence of an association. In addition, more samples were genotyped
by Affymetrix platform (i.e. 441 vs 331). Of interest, there was a
nominal positive association between PRST2D and high glycaemic level,
in which previous studies [55,58] with comparable study design and
setting also found similar results in patients with psychosis while others
[56,60] failed to confirm the association.
In agreement with Cohen et al. [62], Mookhoek et al. [10] and
Padmanabhan et al. [60], we found no significant association between
use of antipsychotic drugs and high glycaemic level. Our study in-
dicated that antipsychotics can be associated with high glycemia level
only when genetic susceptibility to SCZ is high given that the associa-
tion was attenuated when we adjusted our model for the interaction
term (i.e., PRSSCZ by high metabolic risk antipsychotics). In contrast,
several longitudinal, randomized control trial and meta-analysis studies
[24-28] found a significant positive association between the use of
antipsychotic drugs particularly olanzapine and clozapine and high
glycaemic level. One possible explanation for this discrepancy may be
that psychiatrists are more aware of the risk and may switch sooner to
low metabolic risk antipsychotic medication, once metabolic dis-
turbances have occurred in daily practice. In addition, the difference in
the age of patients may explain this variation at least in part. In this
study, the mean age was 30 years suggesting they are physically active
Table 1
Background characteristics of patients (N=1129).
Characteristics N=1129
Demographics and lifestyle
Gender, male (%) 75.8
Marital status, not married (%) 85.0
Ethnicity, Caucasian (%) 79.2
Age, median (IQR) years 29.0 (10.0)
Alcohol drinkinga (%) 74.3
Cigarette smokingb (%) 62.3
Disease diagnosis and treatment
Diagnosis, psychotic disorder (Schizophrenia) (%) 96.6
Age of onset of first psychosis, median (IQR) years 21.0 (9.0)
Duration of psychotic illness, median (IQR) years 7.3 (5.2)
First psychotic episode (%) 32.1
Total transition (sibling and controls) to psychosis (%) 0.9
Current use of antipsychotics (any type) (%) 78.8
High metabolic risk antipsychoticsc (%) 25.0
Medium metabolic risk antipsychoticsd (%) 14.9
Low metabolic risk antipsychoticse (%) 11.2
Antipsychotic daily dosage (CPZE), median (IQR) mg/day 300 0.0 (330.0)
Cardiometabolic profile
Glycated haemoglobin (HbA1c), mean (SD) mmol/mol 35.1 (5.9)
Body mass index, mean (SD) kg/m2 26.1 (4.9)
Umbilical waist circumference, mean (SD) cm 95.0 (14.4)
Systolic blood pressure, mean (SD) mmHg 127.2 (15.4)
Diastolic blood pressure, mean (SD) mmHg 79.4 (11.1)
Pulse rate, mean (SD) beat/min 75.6 (15.4)
Triglycerides, median (IQR) mmol/l 1.4 (1.2)
High-density lipoprotein, mean (SD) mmol/l 1.2 (0.6)
Low-density lipoprotein, mean (SD) mmol/l 3.1 (0.9)
Diabetes, Type 2f (%) 2.5
Comorbid diseasesg (%) 13.4
Genotyping platform, Affymetrix 57.1%
CPZE=Chlorpromazine equivalent; SD= Standard deviation;
IQR= Interquartile range; a=Greater than 12 units during the last 12months;
b=Daily use of cigarettes during the last 12months; cIncludes olanzapine and
clozapine; dIncludes risperidone, quetiapine, amisulpiride, pipamperone, levo-
mepromazine and sertindole; eIncludes haloperidol, aripiprazole, bromperidol,
flupentixol, pimozide, sulpiride and zuclopenthixol; f = Self-reported; g= Self-
reported hematologic, hormonal, metabolic, heart, vascular, liver-bilious-pan-
creas-spleen, abdominal/gastrointestinal, and kidney disorders.
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and perform regular exercise. The design of the study, degree of gly-
caemic dysregulation and difference in duration of treatment may also
explain this incongruity [10,24,63]. Our study is cross-sectional in
which the mean HbA1c was 35.1mmol/mol and duration of anti-
psychotics treatment was not clearly known.
In this study, late age of psychosis onset was the strongest predictor
that independently associated with high HbA1c, which is in line with
previous studies that report diabetes and related comorbidities are
more common in older people with SCZ [64,65]. Despite this, it is not
yet clear whether medical comorbidities are more prevalent among
older persons with SCZ or whether these disorders have an earlier age
of onset [64]. It is known that the typical age of SCZ onset is late
adolescence [66] and a recent meta-analysis also concluded that glu-
cose dysregulation occurs starting from the onset of SCZ [12]. In ad-
dition, we found evidence of a nominal association between high
HbA1c and increased body mass index and diastolic blood pressure.
Glycaemic dysregulation among people with SCZ has been attributed to
common diabetogenic factors, such as high body mass index or obesity,
high blood pressure or hypertension, and dyslipidaemia [13,38]. A
large cohort study and meta-analysis of 30 studies conducted in the
general population also concluded that people with elevated blood
pressure are at increased risk of diabetes [67].
In general, the mechanisms of cardiometabolic risk factors and/or
disorders in patients with SCZ are complex and multidimensional that
include polygenic and polyenviromic risk factors, such as the use of
antipsychotic drugs, poor nutrition, smoking, and physical inactivity.
Current studies show that antipsychotic drugs might affect glucose and
lipid metabolisms leading to an increased risk of hyperglycaemia, in-
sulin resistance, type 2 diabetes, dyslipidaemia, and metabolic syn-
drome, and cardiovascular morbidity and mortality, as a result. In ad-
dition, various genes and neurotransmitter receptors, such as dopamine
D2R, histamine H1R, serotonin 5-HT2R, and muscarinic M3R might
also play a significant part in the risk and differential cardiometabolic
effects of antipsychotic drugs. For example, patients with SCZ who are
carriers of risk genetic variants in HTR2C, AMPK, LEP, BDNF, MC4R,
HRH1, NDUFS1, GHRL, LEPR, NPY, MTHFR, FTO, OGFRL1, CNR1, and
CNR1 genes are more prone to weight gain and metabolic syndrome
and eventually T2D [32-36], whereas patients who are carriers of en-
docannabinoid receptor type 1 gene polymorphisms have a lower risk
of antipsychotics induced cardiometabolic dysregulation [68]. Through
extensive characterization of these risk factors and disentangling un-
derlying pathophysiology, it is can be possible to improve the effec-
tiveness of interventions for prevention and treatment [5,37].
The public health burden of the comorbidity between SCZ and T2D
is high and two-thirds of T2D cases in patients with SCZ were un-
diagnosed. In our study, the prevalence rate of self-reported T2D (2.5%)
was lower than the prevalence reports in the Netherlands [7,63,69] and
in other parts of the world [70]. This might be due to under-diagnosis as
reported by Ward and colleagues [70] that up to 70% of T2D among
patients with SCZ were undiagnosed compared to 25–30% in the gen-
eral population. The comorbidity leads to poor functioning, quality of
life, cognitive performance and prognosis of both diseases, and pre-
mature death due to complications [71,72]. Evidence for intervention
strategies to reduce the burden of physical co-morbidity, improve
health outcomes and reduce the mortality gap in patients with psy-
chosis and other severe mental illness are still in their infancy [73].
Therefore, evidence-based care directed at patients with high polygenic
load, body mass index and blood pressure, and who use high metabolic
risk antipsychotics is required to tackle this problem and make sus-
tained progress [73].
Our study has several strengths. First, the glycaemic level was as-
certained based on the laboratory report of HbA1c, which has a high
specificity [6]. In this study, using HbA1c as a biomarker of T2D can
also be validated by the presence of a relatively high level of HbA1c in
Table 2
Univariable regression analyses on the association between HbA1c and polygenic risk scores, clinical and demographic predictors.
Risk factors Unstandardized Coefficients p-value Explained variance (R2) (%)
β(SE)
PRSSCZ 0.69 (0.29) 0.02 1.33
PRST2D 1.03 (0.30) 0.001 2.80
Platform, Affymetrix 1.00 (0.58) 0.09 0.70
Current use of antipsychotics (any type) 1.39 (0.65) 0.03 0.80
High metabolic risk antipsychoticsa 1.04 (0.50) 0.04 0.70
Medium metabolic risk antipsychoticsb 0.73 (0.60) 0.23 0.30
Low metabolic risk antipsychoticsc −0.59 (0.65) 0.36 0.10
Antipsychotic daily dosage (CPZE) mg/day 0.001 (0.001) 0.43 0.10
Interaction termd 1.94 (1.07) 0.07 0.80
Body mass index (kg/m2) 0.28 (0.05) <0.001 5.10
Waist circumference (cm) 0.09 (0.02) <0.001 4.60
Systolic blood pressure (mmHg) 0.05 (0.02) 0.003 1.60
Diastolic blood pressure (mmHg) 0.09 (0.02) 0.0002 2.50
Pulse rate (beat/min) 0.03 (0.02) 0.04 0.80
Triglycerides (mmol/l) 0.55 (0.17) 0.001 1.80
High-density lipoprotein (mmol/l) −0.59 (0.39) 0.13 0.40
Low-density lipoprotein (mmol/l) 1.05 (0.26) 0.0001 2.70
Age of first psychosis onset (years) 0.19 (0.04) <0.0001 4.30
Duration of psychotic illness (years) 0.11 (0.06) 0.07 0.60
≥ one psychotic episode 0.20 (0.49) 0.69 0.001
Gender, male 1.30 (0.58) 0.03 0.80
Ethnicity, non-Caucasian 1.52(0.66) 0.02 0.90
Current age (years) 0.20 (0.03) 0.001 5.40
Alcohol drinkinge −1.12 (0.58) 0.05 0.60
Cigarette smokingf 0.52 (0.51) 0.31 0.20
PRSSCZ= Polygenic risk score for schizophrenia (p-value threshold 0.05 and standardized to a standard normal distribution with mean of 0 and standard deviation of
1), see also Table S3 for the association based on other p-value thresholds; PRST2D=Polygenic risk score for type 2 diabetes (p-value threshold 5× 10−8 and
standardized to a standard normal distribution with mean of 0 and standard deviation of 1); CPZE=Chlorpromazine equivalent; aIncludes olanzapine and clozapine;
bIncludes risperidone, quetiapine, amisulpiride, pipamperone, levomepromazine and sertindole; cIncludes haloperidol, aripiprazole, bromperidol, flupentixol, pi-
mozide, sulpiride and zuclopenthixol; d= PRSSCZ X High metabolic risk antipsychotics; e=Greater than 12 units during the last 12months; f =Daily use of ci-
garettes during the last 12months.
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individuals with self-reported T2D (i.e., 45.1 mmol/mol). Second, the
PRS was constructed using many SNPs discovered from large training
samples. Third, genetic and non-genetic risk factors were studied in a
relatively large number of patients with SCZ, which can offer a less
biased estimate of the association with glycaemic level. This study has
also limitations. First, a single measurement of the HbA1c level was
used to reveal hyperglycaemia and HbA1c is not the most sensitive
measure of glucose-insulin homeostasis. In addition, the genetic archi-
tecture of the HbA1c and T2D might not necessarily the same. Even
though we have evidence that supported missing at random (MAR), in
general, it is difficult to test or prove the mechanism of data missingness
and multiple imputation (MI) is not usually recommended for data
missing not at random (MNAR). However, in this study, MI performed
on MNAR data is unlikely to bias estimates to a greater extent than
complete case analysis [74]. Another limitation was that the associated
risk factors were determined only based on the availability of data in
the GROUP cohort study; as a result, important risk factors, such as
physical inactivity, inflammatory biomarkers, and poor diet, were not
included in the analyses. It was also impossible to infer causality due to
the cross-sectional nature of the study, but to strengthen the estimation
of true effect and overcome this limitation, we used the sum effect of
genetic variants, which is considered as a permanent marker of dis-
eases/symptoms. Furthermore, our effect estimates may suffer from
collider bias due to the use of PRS [75].
5. Conclusions
Glycemic dysregulation in patients with SCZ was not associated
with PRSSCZ. This suggests that the mechanisms of hyperglycemia or
diabetes are at least partly independent from genetic predisposition to
SCZ. Our findings show that the change in HbA1c level can be caused
by at least in part due to PRST2D, late age of illness onset, male gender,
and increased body mass index and diastolic blood pressure. Therefore,
the PRSSCZ may not be an exclusively informative predictor of T2D in
patients with SCZ, rather clinical and demographic diabetogenic pre-
dictors remain still useful in clinical practice. Future studies with more
sensitive measures of T2D, such as HOMA, HOMA2, fasting insulin or
fasting plasma glucose, and PRS based on recently identified genetic
variants are needed. In addition, it is also relevant to investigate gly-
caemic dysregulation among unaffected siblings of patients and other
relevant diabetogenic risk factors, such as inflammation, poor diet, and
physical inactivity. Finally, Linkage Disequilibrium score regression
and common heritability study in a large sample is recommended to
obtain strong evidence of association.
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Table 3
Multivariable regression analysis on association between HbA1c and polygenic risk scores, and clinical and demographic predictors.
Models Included risk factors Unstandardized Coefficients p-value* Model fit criteria
β (SE) BIC AIC LL R2 (%)
1 PRSSCZ 0.69 (0.29) 0.02 2693.13 2681.03 −1337.51 1.33
2 PRSSCZ 0.86 (0.62) 0.17 2699.56 2671.31 1328.66 5.42
PRST2D 1.01 (0.29) 0.001
Platform effect, Affymetrix −0.51 (1.24) 0.68
High metabolic riska 1.65 (0.64) 0.01
Medium metabolic riskb 0.97 (0.79) 0.22
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Platform effect, Affymetrix 0.18 (1.43) 0.90
High metabolic riska 1.46 (1.51) 0.33
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1); PRST2D= Polygenic risk score for type 2 diabetes (p-value threshold 5×10−8 and standardized to a standard normal distribution with mean of 0 and standard
deviation of 1); BIC=Bayesian Information Criterion; AIC=Akaike Information Criterion; LL= Log-Likelihood; aIncludes olanzapine and clozapine; bIncludes
risperidone, quetiapine, amisulpiride, pipamperone, levomepromazine and sertindole; c=Greater than 12 units during the last 12months; d= PRSSCZ X High
metabolic risk antipsychotics; *= P< .05/18 was used to discover the evidence of an association.
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